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The search for elixir of immortality has yielded mixed results. While some of the interven-
tions like percutaneous coronary interventions and coronary artery bypass grafting have
been a huge disappointment at least as far as prolongation of life is concerned, their absolute
beneﬁt is meager and that too in very sick patients. Cardiac speciﬁc drugs like statins and
aspirin have fared slightly better, being useful in patients with manifest coronary artery
disease, particularly in sicker populations although even their usefulness in primary
prevention is rather low. The only strategies of proven beneﬁt in primary/primordial
prevention are pursuing a healthy life-style and its modiﬁcation when appropriate, like
cessation of smoking, weight reduction, increasing physical activity, eating a healthy diet
and bringing blood pressure, serum cholesterol, and blood glucose under control.
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1. Introduction
Mortality has tormented human consciousness since time
immemorial and humankind has perpetually searched for a
therapy that extends life, the so-called Philosopher's Stone. In
this quest, the human race has been only partially successful;
the life-expectancy has certainly increased but only up to a
certain point. ‘‘Nobody has yet achieved even modest life
extension beyond the apparent upper limit of about 120
years’’. Thus, along this road, there have been some successes
but mostly disappointments. Typically, when a ‘‘new therapy’’
is introduced, there is a lot of hope but as its use increases, its
side-effects also become apparent, which starts a whole new
drive toward next generation of this therapy which is safer and
more effective, but then ever newer side-effects come up again
and this cycle goes on and on, something like ‘‘Carrot and the
Horse.’’ Further, the effects of a new therapy are more
remarkable when disease has already occurred (secondary
prevention) and already reduced life-expectancy as a result ofthis disease; the more severe/serious the disease, the greater
possible beneﬁt of the therapy. However, although effective
therapy may reduce the mortality arising of this disease, it
practically never brings it back to normal, ‘‘the Zenos's Paradox.’’
Recently, advanced technology has provided us with two
highest-proﬁle treatments for coronary artery disease (CAD):
coronary artery bypass grafting (CABG) and percutaneous
coronary interventions (PCI). Each intervention in itself
promised a lifesaving relief and consequently was embraced
enthusiastically by physicians and even lay public. Both these
techniques indeed often provide rapid, dramatic reduction of
the alarming pain/angina associated with the disease. Yet,
when it comes to prolonging life, their track-record is near
dismal, providing little or no improvement in survival rates
over standard medical and lifestyle therapies except in the
sickest of the patients. Further, these procedures are also
associated with signiﬁcant side effects. ‘‘Doctors generate
better knowledge of efﬁcacy than of risk, and this skews
decision making,’’ says David Jones Ackerman professor of the
culture of medicine.1 But why blame only physicians, even
‘‘patients are wildly enthusiastic about these treatments,’’ he
says. ‘‘There 've been focus groups with prospective patients
who have stunningly exaggerated expectations of efﬁcacy.
Some believed that angioplasty would extend their life
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heart-attack patients. But for patients with stable coronary
disease, who comprise a large share of angioplasty patients, it
has not been shown to extend life expectancy by a day, let
alone 10 years – and it's done a million times a year in this
country.’’
So are there any interventions at all which can increase the
expectancy of life, particularly in context of cardio-vascular
conditions?
2. History of increase in life-expectancy
Worldwide life-expectancy at birth was 30.9 years in 1900, 46.7
in 1940, 61.13 in 1980.2 As seen, there was a dramatic
improvement in life-expectancy after 1940 which could be
attributed to three factors:
1. A wave of global drug and chemical innovations: penicillin,
streptomycin, vaccines, discovery of DDT, etc.
2. Spread and availability of medical and public health
technology to all, including poorer countries.
3. Change in international status (value) of health which
practically became a ‘‘right,’’ upgraded from mere ‘‘desir-
able.’’
While early improvement in life-expectancy was a result in
control of infectious diseases, subsequent improvement
occurred as a consequence of focus on life-style diseases.
From 1991 to 2004, life-expectancy in US improved by 2.33
years mostly by medical innovation (discovery and availability
of new drugs) but also addressing problems like smoking and
obesity.3 In context of CVS diseases, mortality from heart
disease in the US fell by more than half between 1950 and 1995,
with a resultant increase in life-expectancy of approximately
3½ years, half to two-thirds of which has been attributed to
coronary care units, treatment of hypertension, and medical
and surgical treatment of CAD.4,5
3. Approaches to improving life-expectancy
Improvement of life-expectancy with any maneuver essen-
tially depends on:
Severity of disease – Baseline mortality is the most
important factor operative on lifespan-gain from any proce-
dure. Diseases with a higher baseline annual mortality rate
demonstrated more lifespan gained. Thus, therapeutic man-
euvers provide more survival beneﬁt in secondary prevention
than primary or primordial prevention.
Duration for which intervention is applied – age of the
patient.
4. Primordial prevention – healthy individual
4.1. Caloric restriction
Caloric restriction (CR) is the only consistently reproducible
experimental means of extending lifespan. Laboratoryexperiments show markedly decreased morbidity in laborato-
ry mammals that are fed to only 80% full.6 Indirect human
proof comes from Okinawa, a region in Japan which boasts one
of the longest life expectancies for its population in the world
as also having a signiﬁcantly large population of centenarians
(living within the region) despite being one of the poorest
regions in the country (being the bottom ranked in socioeco-
nomic indicators for Japan). This is attributed to diet, high
levels of physical activity, and strong cultural values that
include good stress-coping abilities. Among the peculiarities of
culture, Okinawa culture embraces Hara Hachi Bu, which
means to eat only until 80% full.7 Further, studies on the oldest
living natural population in the world, the Seventh Day
Adventists living in California, support these ﬁndings.8 Long-
term human trials of CR are now being done. More recent work
reveals that the effects long attributed to caloric restriction
may be obtained by restriction of protein alone, and
speciﬁcally of just the sulfur-containing amino acids cysteine
and methionine.9,10
4.2. Increased physical activity
Undertaking regular exercise (jogging) increases the life-
expectancy of men by 6.2 years and women by 5.6 years, as
per data from the Copenhagen City Heart study presented at
the EuroPRevent2012 meeting. It showed that between one
and two-and-a-half hours of jogging per week at a ‘‘slow or
average’’ pace delivered optimal beneﬁts for longevity.11
4.3. Metformin
A study by Bannister and co-workers revealed that patients
with type 2 diabetes mellitus (DM) initiated with metformin
monotherapy not only had 38% better survival than those with
DM and treated with sulphonylurea (0.62, 0.58–0.66), but
unexpectedly also survived 15% longer than even matched,
non-diabetic controls (0.85, 95% CI 0.81–0.90). This brings out
an interesting prospect of metformin as ﬁrst-line therapy and
may imply that metformin may confer beneﬁt even in non-
DM.12
4.4. Geroprotectors
Experimental proof of this class of drugs comes from
sirolimus. It is an immune-modulator (also the drug in
drug-eluting stent) which was found to lengthen the mices'
lives by up to 14%. Likewise, everolimus was found to partially
reverse the immune deterioration that normally occurs with
age in a pilot trial in people over 65 years. The drug acting by
inhibiting a protein called mTOR (interestingly mTOR also
seems to be affected by calorie restriction) improved partici-
pants' immune response and is involved in sensing the level of
nutrients available within cells, shifting cells into energy-
conserving mode, which has anti-aging effects, including that
on the immune system.13
In addition to rapamycin analogs, resveratrol, found in
grapes, and pterostilbene, a bio-available substance found in
blueberries, have also shown favorable response.14 Scientists
estimate that these drugs could increase life-expectancy by 10
years.
Table 1 – Reduction of life-expectancy with risk factor.
Risk factor Reduction in
life-expectancy (years)
Smoking 13.9
Obesity 4
Physically inactive in leisure time 3.6
High blood pressure 2.4
Vegetable/Fruit intake <5 cups/day 1.3
Table 2 – Improvement in life-expectancy with control of
risk factor.
Risk factor reduction Improvement in
life-expectancy (years)
Male
Smoking cessation 2.3
DBP reduction ≤88 mmHg 1.1–5.3
Total cholesterol ≤200 mg/dl 0.5–4.2
Reduction of weight 0.7–1.7
Female
Smoking cessation 2.8
DBP reduction ≤88 mmHg 0.9–5.7
Total cholesterol ≤200 mg/dl 0.4–6.3
Reduction of weight 0.5–1.1
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Investigators from The Scripps Research Institute, Mayo Clinic
and other institutions have identiﬁed a new class of drugs that
in animal models dramatically slows the aging process,
alleviating symptoms of frailty, improving cardiac function,
and extending a healthy lifespan. The 2 drugs are dasatimib
(an anti-cancer drug) and quercetin (a natural compound
found in many fruits, vegetables, leaves, and grains), an
antihistamine and anti-inﬂammatory – which can kill senes-
cent cells. Senescent cells are cells which have stopped
dividing and accumulate with age, are a non-productive
burden on the total cell population, and accelerate the aging
process.15
4.6. Genome sequencing
Geneticist Craig Venter announced that he is pursuing a goal of
extending and enhancing the healthy and high performance
life-span by employing the power of human genomics,
informatics, next-generation DNA sequencing technologies,
and stem cell advances.
4.7. Maintaining ideal cardiovascular health
In the middle ages of human life-span, the major diseases
limiting the life-expectancy are cerebro-vascular diseases and
cancer. Thus, it is not surprising that attempts to prevent the
occurrence of CVS diseases (primordial prevention) would have
an impact on increasing life-expectancy. The best way to do that
seems to be to remain at a level of health which does not permit
risk factors to appear (as deﬁned by American Heart Association
[AHA]). It has been suggested that community-based primordial
prevention is capable of reducing cardiac deaths by 90% and
prolonging life-expectancy by 10 years.16,17 It involves following
health behavioral lifestyle characteristics:18
1. Not smoking or quitting over 1 year ago.
2. A body mass index ≤ 25 kg/m2.
3. Exercising at a moderate intensity ≥150 min (or 75 min at
vigorous intensity) each week.
4. Eating a ‘‘healthy diet’’: adhering to four to ﬁve important
dietary components
- sodium intake, 1.5 g/day;
- sugar-sweetened beverage intake, 36 oz weekly;
- 4.5 cups of fruits and vegetables/day;
- three 1 oz servings of ﬁber-rich whole grains/day;
- two 3.5 oz servings of oily ﬁsh/week.
5. Maintaining total cholesterol ≤ 200 mg/dl.
6. Keeping blood pressure ≤ 120/80 mmHg.
7. Maintaining fasting blood glucose ≤ 100 mg/dl.
5. Primary prevention of CAD
5.1. Risk factor modiﬁcations
Mere presence of risk factors leads to reduction in life-
expectancy (Table 1). Thus logically, correction of risk factorswill be expected to lead to at least partial restoration of life-
expectancy (Table 2). Measures used in primary prevention
customarily include smoking cessation, diet modiﬁcation,
physical activity, weight management, and correction of high
blood pressure. Since the reduction of life-span is maximum
with smoking, smoking cessation is likely to beneﬁt most and
it has been estimated that the risk attributable to smoking
returns to baseline (nearly 14 year gain in life-expectancy) after
5 year of smoking cessation.19 Likewise, a 10 mm drop in
systolic blood pressure may reduce cardiovascular mortality
by up to 40%.20
Another study noted that on average, male smokers would
gain 2.3 years from quitting smoking; males with hypertension
would gain 1.1–5.3 years from reducing their diastolic blood
pressure to 88 mmHg; men with serum cholesterol levels
exceeding 200 mg/dl would gain 0.5–4.2 years from lowering
their serum cholesterol level to 200 mg/dl; and overweight
men would gain an average of 0.7–1.7 years from achieving
ideal body weight. Corresponding projected gains for at-risk
women are 2.8 years from quitting smoking, 0.9–5.7 years from
lowering blood pressure, 0.4–6.3 years from decreasing serum
cholesterol, and 0.5–1.1 years from losing weight.21 Eliminat-
ing coronary heart disease mortality is estimated to extend the
average life-expectancy of a 35-year-old man by 3.1 years and a
35-year-old woman by 3.3 years.22
5.2. Statins
Statins have been hailed by many as ‘‘wonder drugs’’, with
some physicians suggesting mass treatment of population. Dr
John Reckless, chairman of Heart UK and a consultant
endocrinologist at Bath University, went as far as suggesting
they should be added to the water supply. Some advocate it
being put in table salt like ‘‘Iodine.’’ The question is whether
Table 3 – Risk–benefit analysis of ASA in primary prevention.
Primary prevention Beneﬁt (number of patients in whom
a major vascular event is avoided
per 1000/year)
Harm (number of patients
in whom a major GI bleeding
event is caused per 1000/year)
Men at low-to-high cardiovascular risk 1–3 1–2
Essential hypertension 2 1–2
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to be? Particularly in context of primary prevention (what to
talk of primordial prevention), their role is controversial.
While early trials predicted a modest reduction in mortality
and a meta-analysis (14 randomized control trials (RCT);
34,272 participants) demonstrated an all-cause mortality
reduction of 16% (RR 0.84, 95% CI 0.73–0.96), the analysis was
criticized because many of the trials included diabetics and
patients with micro-albuminuria (now considered CAD
equivalents) and so these trials were not purely of primary
prevention.21 On the other hand, another meta-analysis of 11
RCTs involving 65,229 individuals completely free from CVD
at baseline demonstrated that use of statins in this high-risk
primary prevention setting was not associated with a
statistically signiﬁcant reduction (risk ratio, 0.91; 95%
conﬁdence interval, 0.83–1.01) in the risk of all-cause
mortality.23 Likewise, an NNT review for Statin Drugs Given
for 5 Years for Heart Disease Prevention (Without Known
Heart Disease) revealed that no life was saved consequent to
their use.24
5.3. Aspirin
The role of aspirin (ASA) in primary prevention of CAD is also
controversial. While use of ASA is deﬁnitely of use in
prevention of CAD, the balance between vascular events
avoided and major bleeds caused by ASA is substantially
uncertain. A recent meta-analysis shows that for individuals
without pre-existing vascular disease, the reduction of
cardiovascular events after adding long-term ASA are likely
to be of similar magnitude as the hazards (Table 3).25,26
6. Stable CAD
6.1. Statins
There is little doubt that statins are effective in reducing
mortality and heart attacks in patients with manifest CAD.
Several large controlled trials including 4S, CARE, LIPID, HPS,
TNT, MIRACL, PROV-IT, and A to Z have shown relative risk
reductions between 7% on the low end (in MIRACL) and 32%
on the high end (in 4S), with an average relative risk reduction
of about 20%. However, the sobering aspect is that absolute
risk reductions are much more modest. They range from 0.8%
in MIRACL on the low end to 9% in 4S on the high end, with an
average of 3%. A meta-analysis of data from 90,056
participants in 14 randomized trials of statins found that
across all the RCTs, statin treatment was associated with a
statistically signiﬁcant 12% reduction in all-cause mortality
(RR 0.88, 95% CI: 0.84, 0.91, p < 0.0001). On the ﬂip-side,
majority of patients saw no beneﬁt at all and only 1 in 83 hadtheir lifespan extended (was saved from a fatal heart
attack).27,28
6.2. ASA
The classic Antiplatelet Trialists' Collaboration (an analysis of
RCTs of anti-platelet therapy among more than 54,000 high-
risk patients with prior evidence of cardiovascular disease)
revealed that ASA therapy reduced by about ¼ the risk of
composite of nonfatal MI, nonfatal stroke, and vascular death
(vascular event). Practically, this beneﬁt translated to reduc-
tion of 1 vascular event out of 50 patients treated for 1 year.29
6.3. Renin angiotensin system
Nishino and co-workers investigated the effect of angiotensin-
converting enzyme inhibitors (ACE-I)/angiotensin receptor
blockers (ARB) on survival beneﬁts in patients with stable
CAD (CAD but without MI). They found that all-cause (5.2% vs.
5.6%, p = 0.56) and cardiovascular (3.2% vs. 3.0%, p = 0.23)
mortality were similar regardless of whether ACEI/ARB were
used or not.30 On the other hand, HOPE study showed that ACEI
therapy may reduce SCD mortality in those with CAD, stroke,
peripheral vascular disease, or diabetes and at least one other
cardiovascular risk factor. Over a mean follow-up period of ﬁve
years, the relative risk of SCD was reduced by approximately
40%, although the absolute risk was low in both treatment and
control groups (0.8% vs. 1.3%, respectively).31
6.4. Beta blockers
A post-hoc analysis of CHARISMA trial revealed that in known
CAD but without MI, b-blocker use was not associated with
lower ischemic outcomes, but rather a trend toward a higher
stroke risk (3.5% versus 1.5%; hazards ratio, 2.13; 95%
conﬁdence interval, 0.92–4.92; p = 0.079).32
6.5. CABG
First successful CABG procedure was performed by Rene
Favaloro of the Cleveland Clinic in 1968. Favaloro's report ﬁred
the imagination of many surgeons, initially operating on
stable patients but as skill was acquired on ever-sicker
patients, and even during MI. Within next decade cardiac
surgeons were performing 100,000 bypass procedures per year
based only on case reports with no single trial available to
justify its usefulness. ‘‘Surgeons said trials were totally
unnecessary, as the logic of the procedure was self-evident,
you have a plugged vessel, you bypass the plug, you ﬁx the
problem, end of story.’’ But there was 'a ﬂy in the ointment,'
The ﬁrst RCT of CABG, from Veterans Administration
hospitals, published in 1977 revealed that there was no
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versus those receiving standard medication. During this time,
there were two other separate multicenter RCTs: the European
Coronary Surgery Study and the Coronary Artery Surgery
Study which showed however, that in some high risk sub-set
of patients of CAD; signiﬁcant obstruction of the left main
coronary artery, triple-vessel CAD and left ventricular (LV)
systolic dysfunction, and two-vessel CAD plus proximal
left anterior descending artery disease there could be a
beneﬁt.33–35 However, even this survival advantage vanished
on longer-term follow-up (12 years or more).36 On the other
hand, a recent network analysis evaluating 95 trials and 93,553
patients did reveal that CABG reduced an all cause mortality by
20% (rate ratio 0.80, 95% credibility interval 0.70–0.91). Thus,
the current evidence shows that CABG may improve survival
for a few patients with the most severe forms of CAD, but for
most others while it relieves symptoms, it may not improve
life-expectancy.
6.6. Percutaneous coronary angioplasty
The issue with PCI is even more contentious. Like CABG, PCI
rates went from zero to 100,000 procedures in no time with no
clinical trial to assess long-term outcomes, based just on the
logic of the procedure and patients' reports of how much
better they felt. Yet, the ﬁrst clinical trials, which appeared
around early 1990s, showed no survival beneﬁt of elective
angioplasty as compared with medication. However, here the
physicians took a different approach, because by the time trial
results came (negative results), the interventionists claimed
that they had moved to next-generation devices; on the other
hand, the now evaluated procedure was already out-dated
and therefore the trial meaningless. However, the matter of
fact is that there are several small trials in stable CAD patients
comparing PCI with medical therapy (with both single and
multi-vessel disease). While most have reported only limited
follow-up data, they do show that PCI signiﬁcantly improved
angina relief and short-term exercise tolerance, but did not
signiﬁcantly reduce death, MI, or need for subsequent
revascularization.37–39 In fact, a meta-analysis of six RCTs
comprising 1904 patients revealed that the only outcome
measure that favored PCI (compared with medical therapy)
was angina relief (OR 0.70; 95% CI 0.50–0.98). However, for
death, MI, and need for repeat revascularization, the ORs
trended strongly in favor of medical therapy (29–42%) versus
PCI. Further, the need for subsequent CABG was nearly 60%
higher with PCI, although the situation may be slightly
different when newer generation of drug eluting stents is
used.40,41On positive side, like CABG, there are certain subsets
of patients where there may be survival advantage with PCI,
particularly primary PCI. A comparative-effectiveness study
of CABG surgery in a population of real-world patients
(105,156 propensity score-matched Medicare patients) has
shown that CABG surgery may be associated with approxi-
mately 19 days increase in life-expectancy versus PCI.42 On
the other hand, in a study Berger and co-workers revealed that
in those high-risk anatomic subsets in which survival is
prolonged by CABG (versus medical therapy), revasculariza-
tion whether by PCI or CABG yielded equivalent survival over
seven years.437. ACS/AMI
7.1. Statins
RIKS-HIA study demonstrated that early statin (started before
or at the time of hospital discharge) therapy could lead to a 25%
reduction in 1-year mortality (relative risk, 0.75; 95% CI, 0.63–
0.89; p = .001) in hospital survivors of AMI.44 Even in individuals
with elevated CRP (a marker of inﬂammation/ACS), statin
therapy could lead to a gain of life-expectancy, 6.6 months in
male and 6.4 months in female.45
7.2. ASA
In the ISIS-2 study, the use of ASA (162 mg chewed) in AMI was
associated with nearly 1/4th reduction of vascular mortality.46
In other ACS (Non MI), ASA use has been associated with
reduction in fatal or nonfatal MI by 50–70% during the acute
phase and by 50–60% at 3 months to 3 years.47,48
7.3. Beta blockers
Several prospective RCTs trials of beta-receptor blockade
therapy after AMI have demonstrated an improvement in
survival, primarily due to a decreased incidence of SCD.49–51
The beneﬁt was notable right from the beginning (in the ﬁrst
few months) and persisted on long-term follow-up (even up to
6 years). At follow-up, beyond a year, these studies show a 30–
45% relative reduction in SCD, with an absolute sudden death
incidence reduction of 1.3–6.2%. On the other hand, CHARISMA
Trial showed that b-blocker use in patients with prior MI but no
heart failure was associated with a lower composite cardio-
vascular outcome end-points but no reduction in mortality.32
The ACC/AHA committee on chronic stable angina recom-
mends beta-blockers as the ﬁrst-line therapy in post-MI
patients based on evidence of improved mortality.52
7.4. Renin angiotensin system
CREDO-Kyoto PCI/CABG registry cohort-2 investigators studied
nearly 12,000 patients undergoing ﬁrst PCI and demonstrated
that patients with MI, treated with ACEI/ARB had a survival
advantage: 3-year all-cause mortality (6.6% vs.11.7%,
p < 0.0001). However, this beneﬁt was not manifest in non-
MI patients.53
7.5. Thrombolysis
The Fibrinolytic Therapy Trialists' Collaborative Group evalu-
ated 9 trials including 58,600 patients and demonstrated
highly signiﬁcant absolute mortality reductions of about 30 per
1000 for those presenting within 0–6 h and of about 20 per 1000
for those presenting 7–12 h from onset but a (statistically)
uncertain beneﬁt of about 10 per 1000 for those presenting at
13–18 h. The beneﬁt was observed both among patients
presenting with ST elevation or bundle-branch block –
irrespective of age, sex, BP, heart rate, or previous history of
MI or diabetes – and was greater, the earlier the treatment
began.54 The temporal effect on survival was demonstrated in
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patients in GISSI-1 trial showed that in patients randomized to
streptokinase (or control treatment) within 1 hour of symptom
onset, there was a 51% reduction in mortality (studied at 21
days).55
7.6. Percutaneous coronary angioplasty
A meta-analysis of 10 randomized trials demonstrated the
superiority of PCI over thrombolytic therapy in preventing
death and other adverse clinical outcomes: a reduction of
mortality by more than 1/3rd (34%, p = 0.02), an absolute risk
reduction for death of approximately 2%, death or nonfatal
AMI (11.9% vs. 7.2%, p < 0.001), all stroke (2.0% vs. 0.7%,
p = 0.007), and hemorrhagic stroke (1.1% vs. 0.1%, p < 0.001).56
8. Congestive heart failure
As life-span decreases, as a consequence of severity of disease,
several therapeutic interventions may aid in bringing down
the mortality.
8.1. Drugs
Several drugs may be effective in this situation and the
mechanism may involve either preventing the development of
lethal heart rhythms or by limiting the on-going damage to
heart muscle (Table 4).57
1. ACE-I.
2. ARBs.
3. Beta-blockers.
4. Aldosterone receptor antagonists (but not other diuretics
which can improve symptoms but do not improve survival).
5. Hydralazine/Nitrates.
Beta-blockers, bisoprolol, metoprolol, and carvedilol have
been shown to reduce total mortality in several studies.58–60
The effect seems to be predominantly due to reduction of
mortality from SCD (42% with bisoprolol in CIBIS II, an absolute
risk reduction of 2.7% over a mean follow-up period of 1.3
years) but the effect may also be due to reduction in
ischemia.61
The mechanism of mortality reduction with ACE-I is under
scrutiny. The CONSENSUS trial showed a 31% reduction of
total mortality at 1 year in the enalapril (vs. the placebo group)
but no reduction in sudden death.62 On the other hand, in theTable 4 – Drugs improving life-expectancy in heart failure.
Drug Mortality reduction % 
ACE-I 17–37 
ARB Similar to ACE-I 
Beta blockers 34–65 
Aldosterone Antagonists 15–30 
Hydralazine/Nitrates 43% in African Americans 
Digoxin No Beneﬁt, No harm TRACE study, trandolapril signiﬁcantly reduced the risk of SCD
in post MI patients with LV dysfunction, a 22% relative
decrease and a 3.2% absolute decrease in SCD over a 4-year
period.63
Even, aldosterone antagonists seem to signiﬁcantly reduce
mortality in patients with severe heart failure by reducing
arrhythmic deaths. In the RALES study, over a 2-year period,
the relative risk of SCD was reduced by 29%, and absolute risk
reduced by 3%.64
8.2. Devices
COMPANION trial was a RCT comparing standard heart failure
drug therapy alone, or in combination with either cardiac
resynchronization therapy (CRT) or CRT plus implantable
cardioverter-deﬁbrillator (ICD) in heart failure patients – NYHA
class III–IV with LVEF ≤35% and QRS width ≥120 ms. They
found that while CRT alone helped, mortality was reduced
equally in both the device arms (with no signiﬁcant improve-
ment of mortality with combined device; CRT/ICD (combo
device)). Thus, use of a combo device in this situation should
be based on the indications for ICD therapy.65
8.3. Surgery
Heart transplantation is the therapy of choice for the
treatment of end stage heart failure and has been shown to
improve not only life-span but also exercise capacity and
quality of life.66
In patients of dilated cardiomyopathy, heart failure and
signiﬁcant mitral regurgitation, there are some data, which
suggest that mitral valve surgery may be associated with
reduction in mortality as well as improvements in quality of
life.67
9. Life-sustaining therapies
Life-sustaining therapy is any intervention, technology, or
treatment that forestalls the moment of death or simply those
therapeutic maneuvers withholding or withdrawing them
would lead to termination of life. Thus, by deﬁnition, these
interventions have the effect of increasing the life span of the
patient. Many ‘‘therapies’’ may qualify this category: mechan-
ical ventilation, cardio-pulmonary resuscitation, vasoactive
agents, dialysis, artiﬁcial nutrition, hydration, antibiotics,
blood replacement products as well as those speciﬁc for
cardiac condition such as ICDs (for secondary prevention ofOther beneﬁts
Symptomatic beneﬁt
Symptomatic beneﬁt
Reduce hospitalizations, risk of sudden death, improve LV function,
exercise tolerance; and reduce heart failure functional class
Reduction in hospitalizations and sudden death
Symptomatic beneﬁt
Symptomatic beneﬁt, reduce hospitalization
Table 5 – Disease stage and impact of various therapies in prolongation of life.
Intervention Primordial
prevention
Primary
prevention
Stable
CAD
Unstable
CAD
CHF End-stage
heart disease
Life-style intervention + ++ +++ +++ +++ NA
Statins   + ++ NA NA
ASA   + ++ NA NA
ACE-I/ARB   + ++ +++ NA
Beta-blockers    + +++ NA
Aldosterone antagonists     ++ 
ICD     + +
CRT     + +
Cardiac assist devices      +
Mechanical ventilation      +
CPR      +
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chanical assist devices (for advanced decompensated heart
failure).68
10. Drugs or life-style modiﬁcation
The efﬁcacy of either strategy depends on the stage of medical
science intervention (Table 5). Since life-style diseases now
account for nearly 2/3rd of all serious diseases worldwide, a
strategy targeted toward these diseases is likely to yield most
results.69
Drugs are powerful, indispensable weapons against CVD
once it develops. However, its value in prolongation of life may
not be that impressive in stable conditions: in stable CAD,
absolute reduction of mortality with drugs is in the range of 1%
in this situation. The beneﬁt of therapeutic interventions
(drugs and devices) increase with severity of disease, in
the range of 5–10% absolute risk reduction in ACS and in the
range of 10% with CHF. However, because these strategies are
expensive, and they certainly have at least some side effects;
they alone may not be sufﬁcient. In contrast, a healthy lifestyle
is inexpensive, safe, and effective.
In primary prevention, risk factor modiﬁcation can be a
very effective strategy contributing to absolute mortality
reduction in the range of 5% with a combination of all these
strategies. On the other hand, role of drugs (in this subset), if at
all, is controversial and a matter of on-going debate.
In a perfectly healthy individual (primordial prevention),
the only maneuvers which seem to help are adhering to a level
of health which does not permit risk factors to appear (an ideal
life style), a strategy capable of reducing cardiac deaths by 90%,
and prolonging life-expectancy by 10 years. However, while
life-style modiﬁcations are effective they are not simple to
implement. It requires change and persistence (adherence to
change). Thus, going beyond mere medical care, psychological
and nutritional counseling, social and family support may also
be required to manifest a life-time behavior modiﬁcation.
11. Conclusions
The inevitability of death has been instrumental in search for
therapy that extends life, the ‘‘elixir of life.’’ Over the course of
eons, several interventions have been discovered which helpin prolonging life but only in a special circumstance. In
general, the more severe the disease and the longer the (time)
life-saving intervention is applied, the greater the beneﬁt. PCI
and CABG are more useful in sicker patients with CAD while
statins, ASA, and ACE-Inhibitors are clearly beneﬁcial in any
CAD, although magnitude of beneﬁt is still small, if any, when
used in primary prevention.
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